A randomised cross over pilot study of inhaled tobramycin as a treatment option for hospitalised patients with cystic fibrosis versus standard treatment of intravenous tobramycin

This study is looking at a different way to deliver a common antibiotic called tobramycin to people with cystic fibrosis who have a lung flare-up (called an exacerbation). Normally, tobramycin is given directly into a vein (intravenously). This study will test whether breathing in the antibiotic through an inhaler gives the lungs enough of the drug to fight the infection just as well. Each participant will receive both methods at different times so researchers can compare how well each one works. You may be eligible if: - You have been diagnosed with cystic fibrosis - You are 6 years of age or older - Your lungs are chronically infected with a bacterium called Pseudomonas aeruginosa - Your lung function (FEV1) is above 25% - You are being admitted to hospital for a lung infection flare-up You may NOT be eligible if: - You have a fever above 38.0°C - You are allergic to aminoglycoside antibiotics - Your kidneys are not working well enough (creatinine clearance below 50 mL/min) Talk to your doctor about whether this trial might be right for you.